SWOG clinical trial number
S1600

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Closed
Phase
Accrual
100%
Abbreviated Title
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Status Notes
S1600 study will be permanently closed to accrual, effective 10/20/2023.
Activated
02/21/2019
Closed
10/20/2023
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Symptom Control and Quality of Life
Genitourinary Cancer

Treatment

Placebo Immune-modulating drink

Eligibility Criteria Expand/Collapse

Tissue diagnosis of primary cell carcinoma of the bladder by TURBT or partial cystectomy. No evidence of unresectable disease or metastatic disease as assessed by exam under anesthesia or imaging (CT, MRI, PET). Plans for the cystectomy to be performed within 28 days after registration. Surgery must be planned to be performed under pre-approved, study-specific surgical guidelines (see Section 7.3). Must have completed any neoadjuvant chemotherapy or immunotherapy (intravesical or systemic) >/= 14 calendar days prior to registration and any toxicities resolved to at least Grade 2. May have a history of radiation therapy. Radiation therapy must have been completed >/= 180 days prior to registration. May have a history of prior partial cystectomy. Prior partial cystectomy must have been completed at least 180 days prior to registration. Must not have planned adjuvant chemotherapy within 90 days after radical cystectomy. >/= 18 years of age. Must be able to swallow liquid and have no refractory nausea, vomiting, malabsorption, or significant small bowel resection that would preclude adequate absorption. Patients on tube feeding are not eligible. Must have baseline nutrition status assessed using the Scored Patient-Generated Subjective Global Assessment (PG-SGA) by a clinician or licensed healthcare practitioner within 14 days prior to registration and must not have a global category rating of Stage C (severely malnourished). Must not have galactosemia. Must not have known active viral infections such as human immunodeficiency virus (HIV) or hepatitis, as these chronic viral infections may cause cachexia and immunodeficiency and thus alter the biology regarding the study endpoints. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Prostate cancer found at cystectomy would not be considered a prior malignancy. Must not be pregnant or nursing as the conditions preclude candidacy for radical cystectomy. Must consent and be willing to have specimens collected and submitted as described in Section 15.1. must be offered the opportunity to participate in additional specimen banking as outlined in Section 15.2. Must consent and provide their telephone contact information for four 24-hour dietary recall phone interviews to be conducted by staff at the Exercise, Diet, Genitourinary, & Endocrinology Laboratory (EDGE) Research Laboratory (see Sections 7.1c, 7.7e, and 15.3). Must be able to understand and speak English and/or Spanish because the dietary recall phone interviews will only be conducted in English or Spanish.

Publication Information Expand/Collapse

2024

Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600)

J Hamilton-Reeves;J Unger;J Holzbeierlein;DL Lew;J Mark;S Daneshmand;J Kukreja;E Lee;W Tabayoyong;D Hershman;M Fisch;NL Henry J Clin Oncol 42, 2024 (suppl 16; abstr 4501); ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session

2018

A Randomized Phase III Double-Blind Clinical Trial (S1600) Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

J Hamilton-Reeves;J Holzbeierlein;J Unger;D Lew;M Fisch;NL Henry J Clin Oncol 36(suppl 6S; abstr TPS529); ASCO GU Symposium (February 8-10, 2018, San Francisco), poster, abst TPS529

Other Clinical Trials

SWOG Clinical Trial Number
S2312
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200